Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 7;4(9):239.
doi: 10.4172/2155-6113.1000239.

Chromium Therapy for Insulin Resistance Associated with HIV-Disease

Seth A Stein  1 , Margaret Mc Nurlan  2 , Brett T Phillips  2 , Catherine Messina  3 , Dennis Mynarcik  1 , Marie Gelato  1
Affiliations

Chromium Therapy for Insulin Resistance Associated with HIV-Disease

Seth A Stein et al. J AIDS Clin Res. .

Abstract

Objective: With the advent of highly active anti-retroviral therapy, HIV disease has become a chronic condition, but with a number of metabolic complications including insulin resistance and diabetes mellitus, dyslipidemia and hypertension and an increased incidence of atherosclerosis. The aim of the current study was to test the safety and efficacy of chromium picolinate for HIV- associated insulin resistance.

Materials/methods: The study was a randomized, double-blind, placebo-controlled trial with subjects receiving 500μg of chromium picolinate or placebo twice daily for two months. HIV- infected subjects were selected based on a fasting concentration of plasma glucose greater than 5.5mmol/L or a plasma glucose concentration of greater than 7.7mmol/L (but less than 11mmol/L) 2h after oral ingestion of 75g of glucose. Insulin sensitivity was assessed with a hyper-insulinemic-euglycemic clamp and glucose tolerance was assessed with the oral glucose tolerance test. Subjects were monitored closely for alterations in viral load, CD4+ cells, hemoglobin and hematocrit, kidney and liver function, and fasting lipid profiles.

Results: Forty-three subjects were enrolled and 39 completed the protocol (20 in the chromium-supplemented and 19 in the placebo arm). Following chromium-supplementation, there were no significant changes in either insulin sensitivity or glucose tolerance. There was a significant improvement in serum HDL cholesterol concentration in the group supplemented with chromium.

Conclusions: Chromium picolinate supplementation at this level was well-tolerated, but overall was not an effective therapy for insulin resistance in these HIV-infected subjects.

Keywords: Chromium picolinate; Glucose intolerance; Prediabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation of fasting plasma glucose concentration with insulin sensitivity assessed with a hyperinsulinemic-euglycemic clamp.
See this image and copyright information in PMC

References

    1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62. - PubMed
    1. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis. 2010;208:222–227. - PubMed
    1. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745–2749. - PubMed
    1. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999;13:F63–F70. - PubMed
    1. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–1184. - PubMed

LinkOut - more resources